Condition

Non-metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8
Recruiting4
Common interventions19
Lead sponsors shown3
Advertisement

Clinical trials

8 shown
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT TreatmentNCT07538843 · 2026-07-31
RECRUITING
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in KoreaNCT06334120 · 2024-09-25
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29
RECRUITING
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)NCT05348876 · 2022-08-03
RECRUITING
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United StatesNCT06204302 · 2024-01-05
COMPLETED
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World SettingsNCT06013475 · 2023-08-31
COMPLETED
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World SettingsNCT05362149 · 2022-04-04
COMPLETED
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)NCT03493945 · 2018-05-01
COMPLETED

Trial status mix

COMPLETED4
RECRUITING4

Phase mix

PHASE11
PHASE21
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.